Get the Stockscreener App
80.68
0.28%
-0.23
After Hours:
80.71
0.03
+0.04%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Medtronic Plc stock is traded at $80.68, with a volume of 10.32M.
It is down -0.28% in the last 24 hours and down -3.67% over the past month.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
See More
Previous Close:
$80.91
Open:
$80.62
24h Volume:
10.32M
Relative Volume:
1.42
Market Cap:
$103.48B
Revenue:
$33.20B
Net Income/Loss:
$4.26B
P/E Ratio:
24.52
EPS:
3.29
Net Cash Flow:
$5.47B
1W Performance:
-6.66%
1M Performance:
-3.67%
6M Performance:
-6.41%
1Y Performance:
-0.86%
1-Day Range:
$79.93
$80.81
1-Week Range:
$79.93
$88.28
52-Week Range:
$75.96
$96.25
Medtronic Plc Stock (MDT) Company Profile
Name
Medtronic Plc
Sector
Industry
Phone
01135314381700
Address
BUILDING TWO PARKMORE BUSINESS PARK WEST, GALWAY
Compare MDT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDT
Medtronic Plc
|
80.68 | 110.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
ABT
Abbott Laboratories
|
131.30 | 232.01B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.50 | 155.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
376.62 | 149.89B | 23.22B | 2.86B | 3.58B | 7.40 |
|
EW
Edwards Lifesciences Corp
|
74.99 | 45.10B | 5.54B | 4.18B | 623.10M | 7.00 |
Medtronic Plc Stock (MDT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Upgrade | Citigroup | Neutral → Buy |
| Oct-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-21-24 | Reiterated | Oppenheimer | Perform |
| Aug-15-24 | Upgrade | UBS | Sell → Neutral |
| Aug-14-24 | Downgrade | Stifel | Buy → Hold |
| May-30-24 | Initiated | Goldman | Sell |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-24-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-29-23 | Downgrade | UBS | Buy → Sell |
| Jan-09-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-23-22 | Downgrade | Citigroup | Buy → Neutral |
| Nov-23-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-16-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Aug-24-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Jun-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-27-22 | Downgrade | Needham | Buy → Hold |
| Apr-13-22 | Downgrade | Truist | Buy → Hold |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-04-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-17-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-10-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Dec-15-20 | Upgrade | Goldman | Sell → Neutral |
| Dec-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-08-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Oct-08-20 | Upgrade | Stifel | Hold → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| May-14-20 | Downgrade | DZ Bank | Buy → Hold |
| Mar-30-20 | Downgrade | Needham | Strong Buy → Buy |
| Mar-25-20 | Upgrade | DZ Bank | Hold → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Sell |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-02-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-05-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Feb-04-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Buy |
| Jan-02-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Aug-27-18 | Reiterated | Argus | Buy |
View All
Medtronic Plc Stock (MDT) Latest News
Redburn Atlantic Adjusts Price Target on Medtronic to $101 From $104 - marketscreener.com
JPMorgan Adjusts Medtronic Price Target to $87 From $95 - marketscreener.com
Jim Cramer on Medtronic (MDT): “I Like This Medical Device Powerhouse” - Insider Monkey
Blood Glucose Monitoring (BGM) Devices Market Report 2025: Hospitals Lead in Blood Glucose Monitoring Device Usage, Home Care Grows Fastest - GlobeNewswire Inc.
Endoscopy Devices Global Market Overview 2021-2030 with Forecasts 2024-2030 - GlobeNewswire Inc.
Medtronic to separate diabetes business following recent struggles - MSN
Medtronic Announces Separation From Diabetes Business, CEO Says it’s “In a Really Good Spot” - Insider Monkey
Medtronic has a new Cardiovascular, CST leaders after longtime exec departs - MassDevice
TD Cowen Keeps a Buy on Medtronic (MDT) After Better Growth in Q4 - Insider Monkey
Medtronic PLC stock underperforms Thursday when compared to competitors - MarketWatch
Abbott vs. Medtronic: Which Dividend-Paying MedTech Stock is Better? - Nasdaq
Global Foley Catheters Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~9% by 2032 | DelveInsight - GlobeNewswire Inc.
MDT: RBC Capital Lowers Price Target for Medtronic | MDT Stock N - GuruFocus
Medtronic (MDT) Stock Price Target Lowered by Mizuho Analyst | M - GuruFocus
Medtronic inks expanded distro deal for multi-parameter wearable vital sign monitor - MassDevice
Medtronic's Strong Q4 Performance Sets The Stage For Future Growth - Finimize
Medtronic (MDT) Price Target Lowered by Baird Analyst | MDT Stoc - GuruFocus
Medtronic Cardiovascular Strength Drives Fiscal Q4 Beat, RBC Says - marketscreener.com
Why Medtronic plans to spin out its diabetes business - MedTech Dive
July 3rd Options Now Available For Medtronic (MDT) - Nasdaq
Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon - MassDevice
Medtronic (MDT) Price Target Lowered by RBC Capital Amid Growth Investments | MDT Stock News - GuruFocus
Truist Adjusts Price Target on Medtronic to $92 From $90, Maintains Hold Rating - marketscreener.com
Oppenheimer Adjusts Medtronic Price Target to $92 From $94 - marketscreener.com
Medtronic (MDT) Price Target Lowered but Growth Potential Remains Strong | MDT Stock News - GuruFocus
Medtronic plc (NYSE:MDT) Q4 2025 Earnings Call Transcript - MSN
Medtronic (MDT) Sees Price Target Reduced by Baird | MDT Stock N - GuruFocus
Medtronic to split diabetes business into separate entity, targets IPO - Medical Device Network
Needham Reiterates 'Hold' Rating on Medtronic (MDT) | MDT Stock News - GuruFocus
Baird Adjusts Price Target on Medtronic to $92 From $94, Maintains Neutral Rating - marketscreener.com
Medtronic still hiding behind its status as a dividend aristocrat - marketscreener.com
Medtronic announces intent to separate diabetes business - BioSpectrum Asia
Medtronic : expands its Acute Care & Monitoring portfolio in Europe with a new distribution agreement for the Corsano™ multi-parameter wearable - marketscreener.com
Medtronic PLC (MDT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Moves - Yahoo Finance
Medtronic PLC (MDT) Q4 2025 Earnings Call Highlights: Strong Rev - GuruFocus
Medtronic plc. (MDT) Stock Forecasts - Yahoo Finance
Medtronic Reports Strong FY25 Results and Dividend Increase - TipRanks
Medtronic: Fiscal Q4 Earnings Snapshot - Norwalk Hour
Medtronic to Split Off Diabetes Unit as Tariffs Hit Earnings - MSN
Medtronic aims to sweeten appeal by unloading diabetes unit - BioWorld MedTech
Evercore ISI maintains Outperform on Medtronic, keeps $103 target By Investing.com - Investing.com UK
Evercore ISI Removes Medtronic, Inc. (MDT) from TAP List - StreetInsider
Medtronic stock price target cut to $103 by Evercore ISI - Investing.com UK
Medtronic plc Announces Cash Dividend for the First Quarter of Fiscal Year 2026, Payable on July 11, 2025 - marketscreener.com
Citi cuts Medtronic price target to $98, maintains buy rating By Investing.com - Investing.com UK
Medtronic (MDT) Announces Diabetes Business Separation and Growt - GuruFocus
Medtronic earns CE mark for redo TAVI procedure - MassDevice
Medtronic plc (NYSE: MDT) Stock: Dips Despite Q425 Beat as FY26 Forecast Disappoints - CoinCentral
Medtronic outlines 5% organic revenue growth target and diabetes business separation ahead of FY26 - MSN
Medtronic, Inc. (MDT) PT Lowered to $98 at Citi - StreetInsider
Medtronic plc agreed to Spin-Off New Diabetes Company. - marketscreener.com
Medtronic Plc Stock (MDT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):